Surgical treatment outcomes of primary hepatic sarcomas: A single-center experience

Table 1 Characteristics of the study population

Case	Sex	Age	Pathology	Size (cm)	Operation, R Status	Adjuvant therapy	Recurrence (mo)	Follow-up (mo)	Outcomes
1	M	57	HAS	13.5	Lt. lobectomy, R0		1.7	2.2	Dead
2	F	2	HAS	21	Living donor LT, R0	CTx1	1.8	31.2	Dead
3	M	52	HAS	7.3	Rt. Trisectionectomy, R0		1.2	4.2	Dead
4	F	48	UDS	13	Rt. lobectomy, R0	CTx2	1.6	68.2	Dead
5	M	60	HAS	2.4	Living donor LT, R0	RT	11.0	13.4	Dead
6	F	53	UDS	25	Rt. Trisectionectomy, R2		0	1.3	Dead
7	M	62	HAS	2	Central hepatectomy, R0	RFA	59.9	135.1	Alive
8	F	60	UDS	11.5	Rt. lobectomy, R0	CTx, RT, Exc3	14.6	29.9	Alive
9	M	60	UDS	24	Rt. lobectomy and Rt. Npx, R0	CTx4	1.2	9.9	Dead

¹ICE (ifosfamide/carboplatin/etoposide) 6 cycles.

²VIP (etoposide/ifosfamide/cisplatin) 5 cylcles, AI (doxorubicin/ifosfamide) 5 cycles, docetaxel/gemcitabine 2 cycles.

³VIP (etoposide/ifosfamide/cisplatin) 6 cycles, RT on vertebral metastasis, abdominal wall metastatic tumor excision.

⁴AI (doxorubicin/ifosfamide) 4 cycles, docetaxel/gemcitabine 1 cycle. HAS: Hepatic angiosarcoma; UDS: Undifferentiated sarcoma; Npx: Nephrectomy; CTx: Chemotherapy; RT: Radiation therapy; RFA: Radiofrequency ablation; Exc: Excision.

Table 2 Characteristics of the groups

	Total (n = 9)	Angiosarcoma (n = 5)	Undifferentiated sarcoma (n = 4)	P value
Age (range)1	57 (2-62)	57 (2-62)	56 (48-60)	0.999
Sex, male (%)	5 (55.6)	4 (80)	1 (25)	0.120
Largest tumor size (cm)1	13.0	7.3	18.5	0.142
Tumor number1	1.0	2	1	0.371
AFP1	2.8	2.6	2.8	0.999
CA19-91	13.2	3.2	1970	0.180
Recurrence (%)	9 (100)	5 (100)	4 (100)	0.999
Disease-free survival days1	52 (0-1798)	53 (36-1798)	35 (0-439)	0.221
Death (%)	7 (77.8)	4 (80)	3 (75)	0.866
Survival days1	402	402	596	0.806

¹The numbers are median value. AFP: Alpha fetoprotein.

Table 3 Risk factors for cancer recurrence

	Univariate HR (95%CI)	P value	Multivariate HR (95%CI)	P value
Sex (male)	0.82 (0.20-3.31)	0.779
Age	0.99 (0.96-1.03)	0.694
Pathology (HAS/UDS)	0.50 (0.12-2.07)	0.339	0.63 (0.11-3.55)	0.602
Largest tumor size	1.13 (1.00-1.27)	0.049	1.12 (0.97-1.28)	0.115
Tumor number	1.28 (0.79-2.07)	0.311
AFP	1.02 (0.77-1.33)	0.917
CA 19-9	1.00 (1.00-1.00)	0.527
Adjuvant therapy	0.24 (0.04-1.47)	0.121	0.25 (0.04-1.71)	0.157

HAS: Hepatic angiosarcoma; UDS: Undifferentiated sarcoma; AFP: Alpha fetoprotein; CI: Confidence interval; HR: Hazard ratio.

Table 4 Risk factors for patient death

	Univariate HR (95%CI)	P value
Sex (male)	1.36 (0.30-6.24)	0.693
Age	1.00 (0.96-1.04)	0.922
Pathology (HAS/UDS)	0.99 (0.22-4.47)	0.989
Largest tumor size	1.08 (0.97-1.20)	0.179
Tumor number	1.28 (0.79-2.07)	0.311
AFP	0.99 (0.74-1.31)	0.922
CA 19-9	1.00 (0.99-1.01)	0.677
Adjuvant therapy	0.00 (0.03-2779)	0.002

HAS: Hepatic angiosarcoma; UDS: Undifferentiated sarcoma; AFP: Alpha fetoprotein; CI: Confidence interval; HR: Hazard ratio.